Tramadol Hydrochloride Tablet, Extended Release
Product Images NDC 71205-463

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 71205-463). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-1 (33a5de83 A974 48a5 8ba6 4c1b97515615 01)

Chemical structure of Tramadol Hydrochloride showing its molecular configuration including a methoxyphenyl group, cyclohexanol ring, and dimethylamino group attached to the main structure.*

FDA Label Image

Image-2 (33a5de83 A974 48a5 8ba6 4c1b97515615 02)

A pharmacokinetic line graph comparing plasma tramadol concentrations (ng/mL) over 24 hours for Tramadol Hydrochloride Extended-Release Tablets 200 mg once daily (black circles) and Tramadol Hydrochloride Tablets 50 mg every 6 hours (white circles). The x-axis shows time in hours, and the y-axis shows tramadol concentration.*

FDA Label Image

Image-3 (33a5de83 A974 48a5 8ba6 4c1b97515615 03)

A line graph depicting M1 metabolite concentration (ng/mL) over 24 hours for Tramadol Hydrochloride extended-release tablets 200 mg taken once daily versus immediate-release tablets 50 mg taken every 6 hours. The y-axis shows concentration from 0 to 120 ng/mL, and the x-axis shows time in hours. Two curves compare the different dosing regimens.*

FDA Label Image

Image-4 (33a5de83 A974 48a5 8ba6 4c1b97515615 04)

A line graph titled 'Tramadol Hydrochloride Extended-Release Tablets Study 023 WOMAC Pain Responder Analysis' shows the percent of patients achieving various response thresholds in percent improvement from baseline. It compares Tramadol Hydrochloride Extended-Release Tablets at doses of 100 mg, 200 mg, 300 mg, and 400 mg, and placebo. The y-axis represents the percent of patients achieving response, while the x-axis represents the response threshold percentage from 0 to 100.*

FDA Label Image

Image-5 (33a5de83 A974 48a5 8ba6 4c1b97515615 05)

A line graph titled 'Tramadol Hydrochloride Extended-Release Tablets Study 015 Arthritis Pain Intensity VAS Responder Analysis' showing the percent of patients achieving various response thresholds. The x-axis represents the response threshold as percent improvement from baseline (0 to 100%), and the y-axis shows the percent of patients achieving response (0 to 60%). Two lines compare Tramadol Hydrochloride Extended-Release Tablets and placebo, indicating higher patient response percentages for Tramadol across most thresholds.*

FDA Label Image

71205-463-90 (33a5de83 A974 48a5 8ba6 4c1b97515615 06)

Label for Tramadol HCl 100 mg extended-release tablets, 90 count, manufactured by Lupin Limited Pithampur (M.P.), India, and packaged by Proficient Rx LP. The label includes the ProficientRx logo, NDC 71205-463-90, and notes the product is Schedule IV (C-IV) and prescription only. Tablets are described as white to off-white, circular, biconvex, beveled edge, coated, imprinted with 'L010'.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.